Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Tax Provisions (2019 - 2023)

Denali Therapeutics (DNLI) has disclosed Tax Provisions for 5 consecutive years, with $30000.0 as the latest value for Q4 2023.

  • Quarterly Tax Provisions rose 600.0% to $30000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $24000.0 through Dec 2023, up 104.33% year-over-year, with the annual reading at $102000.0 for FY2025, 50.0% up from the prior year.
  • Tax Provisions for Q4 2023 was $30000.0 at Denali Therapeutics, up from -$6000.0 in the prior quarter.
  • The five-year high for Tax Provisions was $823000.0 in Q4 2020, with the low at -$575000.0 in Q4 2021.
  • Average Tax Provisions over 5 years is -$7900.0, with a median of $10500.0 recorded in 2022.
  • The sharpest move saw Tax Provisions crashed 169.87% in 2021, then surged 600.0% in 2023.
  • Over 5 years, Tax Provisions stood at -$113000.0 in 2019, then skyrocketed by 828.32% to $823000.0 in 2020, then plummeted by 169.87% to -$575000.0 in 2021, then skyrocketed by 98.96% to -$6000.0 in 2022, then soared by 600.0% to $30000.0 in 2023.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $30000.0, -$6000.0, and $27000.0 for Q4 2023, Q4 2022, and Q2 2022 respectively.